Amivantamab-vmjw (amivantamab) is a bispecific EGFR/MET antibody approved for patients with advanced NSCLC with EGFR exon 20 insertion mutations after therapy [42]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.